WORLDiscoveries secures $1M Agri-THERM sale

October 16, 2009

At the official opening of the Institute for Chemicals and Fuels from Alternative Resources (ICFAR), WORLDiscoveries Executive Director Paul Paolatto announced the sale of the first Agri-therm mobile pyrolysis unit to the government of Mexico, through the University of Vera Cruz, for $1 million.

Paolatto says more deals may be in the pipeline.

“We have more than 250 qualified leads around the world,” says Paolatto, adding “there is nothing more important to the team at Agri-therm than to add a decal that says ‘Made in London, ON.’”

The portable unit can be hauled from one farm field to the next to process waste such as corn husks into a solid bio-char and bio-oil. This material then becomes an eco-friendly ingredient in fertilizers, fuels and chemicals, including environmentally friendly insecticides and pesticides.

The patented, mobile pyrolysis unit has been undergoing testing and revisions for the past several years. Pyrolysis uses heat to break down complex chemical substances into simpler substances.

About Agri-THERM, Inc.

Agri-Therm Inc. is a new WORLDiscoveries spin-off company set to transform the agricultural industry with a mobile pyrolysis platform. The platform, which was developed under the leadership of Franco Berruti and Cedric Briens, converts low-value agricultural residue (e.g. corn stalks, trees, manure, etc.) into higher-value, bio-based oil for use as a food additive, fertilizer or fossil fuel substitute in a cost-effective and environmentally friendly manner.


Dr. Kang partners with Sumagen on HIV/AIDS vaccine development

The following is excerpted from the November 18, 2009 Alumni Western article “Inching closer to a cure for AIDS” by Paul Mayne

After more than 20 years of labouring on an HIV /AIDS vaccine, The University of Western Ontario’s Yong Kang continues to inch closer to what would be an historic moment for mankind – a vaccine to prevent the disease that has taken 25 million lives and sees another 35 million infected worldwide.

Developed by Kang and his team at the Schulich School of Medicine & Dentistry, and licensed to Sumagen Canada Inc., the vaccine completed animal toxicology trials in April and following United States Food and Drug Administration (FDA) approval (pending), will begin Phase 1 human trials for its SAV001 AIDS vaccine.

About Sumagen Canada Inc.

Sumagen Canada Inc. is a solely owned subsidiary of Curocom Korea. The company is fully funding Dr. Kang’s continuing work on the HIV/AIDS vaccine development.